Edwards Lifesciences Corporation (EW) Director Schack Wesley W. Von Sells 1,000 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) Director Schack Wesley W. Von sold 1,000 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $104.15, for a total transaction of $104,150.00. Following the sale, the director now owns 2,622 shares in the company, valued at approximately $273,081.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Edwards Lifesciences Corporation (NYSE:EW) opened at $105.24 on Tuesday. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.45. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $21,976.73, a price-to-earnings ratio of 28.77, a P/E/G ratio of 1.86 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The firm had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. During the same period in the prior year, the company posted $0.68 earnings per share. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. equities analysts predict that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Edwards Lifesciences Corporation (EW) Director Schack Wesley W. Von Sells 1,000 Shares of Stock” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/14/edwards-lifesciences-corporation-ew-director-schack-wesley-w-von-sells-1000-shares-of-stock.html.

Several institutional investors and hedge funds have recently modified their holdings of the business. Sabal Trust CO increased its stake in shares of Edwards Lifesciences Corporation by 0.5% in the 2nd quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after acquiring an additional 14 shares during the last quarter. Alps Advisors Inc. increased its stake in shares of Edwards Lifesciences Corporation by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock worth $603,000 after acquiring an additional 14 shares during the last quarter. Alexandria Capital LLC increased its stake in shares of Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after acquiring an additional 19 shares during the last quarter. Veritable L.P. increased its stake in shares of Edwards Lifesciences Corporation by 1.2% in the 2nd quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock worth $738,000 after acquiring an additional 71 shares during the last quarter. Finally, First Bank & Trust increased its stake in shares of Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. First Bank & Trust now owns 4,439 shares of the medical research company’s stock worth $525,000 after acquiring an additional 76 shares during the last quarter. 82.17% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently weighed in on EW. Royal Bank Of Canada restated a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and set a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 target price for the company in a research note on Tuesday, July 18th. SunTrust Banks, Inc. boosted their target price on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Canaccord Genuity reissued a “buy” rating and set a $135.00 target price (down from $155.00) on shares of Edwards Lifesciences Corporation in a research note on Wednesday, October 25th. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $125.17.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply